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On 1 January 2004 the government introduced the policy of
Prescribed Minimum Benefits (PMBs) into the health care
sector. This system obliges health care funders to cover fully a
minimum of 25 conditions for all members of the medical aid
scheme, regardless of the level of scheme. In addition, in terms
of an amendment to the Medical Schemes Act, 1998 (Act No.
131 of 1998), health care funders were allowed to introduce
managed health care protocols provided that these were
developed on the basis of evidence-based medicine taking into
account considerations of cost-effectiveness and affordability,
and provided that provision be made for appropriate
exceptions where the protocol has been ineffective or causes or
would cause harm to the beneficiary without penalty to the
beneficiary. Furthermore, if managed health care entails use of a
formulary or restricted list of drugs, such formulary or
restricted list must be developed on the basis of evidence-based
medicine taking into account considerations of cost-
effectiveness and affordability, and must make provision for
appropriate substitution of drugs where a formulary drug has
been ineffective or causes or would cause harm to the
beneficiary without penalty to the beneficiary. With this in mind I
would like to comment on the implementation of the PMBs in
relation to hypertension and also use a case study to illustrate
the serious problems facing doctors trying to implement good
clinical practice.
The Southern African Hypertension Society (SAHS) recently
published the Hypertension Guideline 2003 in this Journal.1 This
guideline represents a consensus statement of the SAHS
Executive, international speakers at the 13th Scientific Meeting,
South African special interest groups, African hypertension
special interest groups, and invited local national Department
of Health delegates, taking careful consideration of the balance
between best clinical practice and affordability. It should be the
model for the management of hypertension in South Africa. Yet
there is another guideline for hypertension created by the
medical schemes, which although broadly similar to the
Southern African Hypertension Guideline has several
important differences. For instance, the South African guideline
recognises the following compelling indications for angiotensin
receptor blockers (ARBs) — angiotensin-converting enzyme
(ACE) inhibitor intolerance, chronic kidney disease, left
ventricular hypertrophy, cardiac failure, type 2 diabetes with
micro-albuminuria or proteinuria, and prior myocardial
infarction.1  The only compelling indication for an ARB in the
PMBs is type 2 diabetes with micro-albuminuria or proteinuria.
Although ACE inhibitors are also compelling (and sometimes
preferred indications) for these conditions (e.g. heart failure,
prior myocardial infarction), the PMBs take no cognisance of
ACE inhibitor intolerance. It is not appreciated that ACE I
intolerance is not an uncommon problem. A controlled
prospective clinical trial2 found that overall 0.68% of all
patients and 1.62% of black patients may develop angio-
oedema (a life-threatening complication). Cough may occur in
up to 20% of patients, leading to discontinuation of therapy.
The Hypertension Guideline Update also explicitly states
that only long-acting calcium channel blockers (CCBs) should
be used for the treatment of hypertension.1  It is well established
that short-acting CCBs may in fact cause harm.3,4 Furthermore
we have previously reported in the Journal serious problems
caused by substituting CCBs either generically or thera-
peutically in high-risk patients with hypertension.5 The
Medicines Control Council has also issued an advisory
warning on substituting dihydropyridine CCBs either
generically or therapeutically.6 In my opinion, considering the
above, only CCBs that have proven benefits based on
prospective clinical trials should be used for the treatment of
hypertension,7-10 but few of these are available on PMB
formularies. On occasion I have been indirectly pressurised by
medical aids to substitute CCBs for cheaper and unproven
‘equivalents’ contrary to the Medicines Control Council’s
advisory warning.6
The following case study illustrates many problems facing
medical practitioners trying to follow good clinical practice
guidelines. I have treated Mr PT for the past 6 years in
conjunction with his vascular surgeon, cardiologists, and
general practitioner. Briefly, he has widespread vascular
disease.  He has had a  coronary artery bypass graft for
ischaemic heart disease, carotid endarterectomy for transient
ischaemic attack, surgery for abdominal aortic aneurysm,
stenting of the renal arteries for severe bilateral renal artery
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stenosis, stenting of the femoral arteries for claudication, recent
athero-embolus to the left eye, ACE inhibitor intolerance and
severe allergic skin reaction to generic simvastatin. He also has
significant hypercholesterolaemia and mild chronic renal
failure (creatinine 170 µmol/l) with proteinuria and
hypertension. Despite all these chronic conditions he remains
in good health. He has four conditions covered by PMBs,
namely hypertension, chronic renal failure, ischaemic heart
disease, and hypercholesterolaemia. He is a member of
Discovery Health, and I made the following motivation for
non-formulary drugs in a letter to the medical advisor because
I was unable to find appropriate choices on the Discovery
Health formulary or guideline for PMBs:
1. Bisoprolol. The patient has peripheral vascular disease
and atenolol worsens his claudication. As he has a compelling
indication for a β-blocker (ischaemic heart disease and
hypertension), the highly selective β-blocker  bisoprolol is
considered the appropriate choice as it has limited effect on
claudication.
2. Losartan. The patient is intolerant to ACE inhibitors and
therefore requires an ARB according to compelling indications
(hypertension, prior myocardial infarction and chronic kidney
disease). Losartan was suggested as he also has
hyperuricaemia.
3. Zocor. The patient was previously on Zocor 30 mg for
significant hyperlipidaemia and ischaemic heart disease.
Switching to generic simvastatin resulted in a severe allergic
skin reaction. Therefore Zocor 30 mg was suggested.
4. Indapamide SR. The patient has a creatinine of 170
µmol/l. Thiazide diuretics become ineffective at this level of
renal function. The suggested substitution was indapamide SR
in view of its efficacy with impaired renal function and slow
onset of action.
5. Clopidogrel. Despite all these measures for vascular
protection the patient suffered an atherosclerotic embolus to
the eye. He is, therefore, aspirin-resistant and according to his
cardiologist and vascular surgeon requires clopidogrel 75 mg
daily.
At the time of writing in April 2004, the patient informed
me that the motivation had not been accepted in its entirety. I
have yet to receive a reply or phone call from the medical
advisor of Discovery Health to discuss the motivation or
consider alternative options. His general practitioner has been
following this up without success. A formal complaint was
lodged with the Council for Medical Schemes on their
electronic website 6 weeks before I wrote this letter, but I am
still awaiting an acknowledgement.
Besides the common courtesy of a reply to a doctor’s
motivation, the entire issue of the PMBs raises several
important questions: (i) who should be responsible for the
designing of guidelines and determination of appropriate
formularies?; (ii) what protection is available to members of
medical schemes against the denial of properly motivated
considerations for treatment; and (iii) how will the patient
obtain medication until these disputes are resolved?
Additionally the financial implications of using non-
formulary drugs is an important issue as it is appropriate for
medical funders to contain costs of chronic medication. I accept
this principle, but this must be in accordance with current
clinical guidelines, must not be to the detriment of the patient,
and should not ignore that the short-term savings in
medication costs may in some cases result in greater costs in
the long term. This is a complex issue and sometimes difficult
to quantify, but in the case presented above it is self-evident
that the minimal differences in cost of generic and ethical
simvastatin cannot be a factor in the overall cost-effectiveness
of statin therapy in high-risk patients. Additionally, failure to
provide appropriate drugs to prevent progressive renal disease
will ultimately result in the need for dialysis. In relation to the
cost of dialysis, the extra money required for the ARB pales
into insignificance.
I am sure this is not an isolated problem and look forward
to a speedy resolution of these difficulties without
compromising patient care. Issues relating to use of guidelines
and formularies by managed health care companies were on
the agenda of the executive meeting of the SAHS held in June
this year.
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